Merck & Company (MRK)

$135.17 -0.80 (-0.59%)
Market Cap 335.46B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 42.32
Forward PE 49.04
Profit Margin 28.08%
Debt to Equity Ratio 1.22
Volume 10,284,200
Avg Vol 10,071,278
Day's Range N/A - N/A
Shares Out 2.47B
Stochastic %K 75%
Beta 0.19
Analysts Strong Sell
Price Target $138.70

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
corruptmarket
corruptmarket Aug. 19 at 11:59 AM
$MRK can we get 160 today?
0 · Reply
SelfMafia
SelfMafia Aug. 19 at 11:58 AM
$TEM People just finding out that they used the $PSNL platform that $TEM now owns? $MRNA $XBI $MRK 😝
0 · Reply
vermigli
vermigli Aug. 19 at 11:57 AM
$MRK $MRNA I’ve seen this movie before. This is either really great news or how the zombie apocalypse starts!
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 19 at 11:56 AM
$PSNL Holding for a $MRK bid
0 · Reply
bizness1957
bizness1957 Aug. 19 at 11:55 AM
$ARDX $XBI index getting a lift on $MRNA and $MRK phase III results.
0 · Reply
Chickenstick1
Chickenstick1 Aug. 19 at 11:53 AM
$MRNA Wow, what a day... A logistical night it may be with the individualization of each vaccine but incredibly encouraging results. Of course, $MRK could handle the flow, but I think $PFE may get a piece of the action, too. Individualization was always the path forward for MRNA vaccines. Congrats to the guys over at $MRNA , well deserved. The market is going to extrapolate from skin to most tumors.
0 · Reply
PittsburghTrader
PittsburghTrader Aug. 19 at 11:53 AM
$MRK sweet, no Luv yesterday but today a party
0 · Reply
arnolddunn
arnolddunn Aug. 19 at 11:53 AM
$MRK Boo yah! …wish I owned Moderna.
0 · Reply
EingeLTrade
EingeLTrade Aug. 19 at 11:52 AM
MERCK $MRK AND MODERNA $MRNA JUST HIT THE FIRST POSITIVE PHASE 3 RESULT EVER FOR A PERSONALIZED CANCER VACCINE!!!
0 · Reply
yus37
yus37 Aug. 19 at 11:51 AM
$MRNA $MRK
0 · Reply
Latest News on MRK
Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

Aug 19, 2026, 7:35 AM EDT - 25 minutes ago

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

LZB MRNA SKHY

Moderna jumps 54% to $97.52 after Phase 3 INTerpath-001 trial met endpoints

2026-08-19T11:00:14.000Z - 1 hour ago

Moderna jumps 54% to $97.52 after Phase 3 INTerpath-001 trial met endpoints

MRNA

Merck, Moderna: Phase 3 INTerpath-001 trial met endpoints

2026-08-19T10:50:25.000Z - 1 hour ago

Merck, Moderna: Phase 3 INTerpath-001 trial met endpoints

MRNA

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

Aug 19, 2026, 6:48 AM EDT - 1 hour ago

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

MRNA

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

Aug 19, 2026, 6:46 AM EDT - 1 hour ago

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

MRNA

An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.

Aug 19, 2026, 6:45 AM EDT - 1 hour ago

An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.

MRNA

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

Aug 19, 2026, 6:45 AM EDT - 1 hour ago

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

MRNA

Merck upgraded to Outperform from Neutral at Daiwa

2026-08-17T10:20:40.000Z - 2 days ago

Merck upgraded to Outperform from Neutral at Daiwa

Daiwa upgrades Merck to Outperform on pipeline success

2026-08-17T10:18:16.000Z - 2 days ago

Daiwa upgrades Merck to Outperform on pipeline success

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 5 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD JNJ LLY UNH

Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials

Aug 13, 2026, 9:00 AM EDT - 5 days ago

Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

Aug 11, 2026, 12:50 PM EDT - 7 days ago

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

GSK

Merck price target raised to $145 from $130 at Argus

2026-08-11T12:35:52.000Z - 7 days ago

Merck price target raised to $145 from $130 at Argus

Merck discloses 1.21M share holding in Evaxion Biotech

2026-08-10T14:15:17.000Z - 8 days ago

Merck discloses 1.21M share holding in Evaxion Biotech

EVAX

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Aug 7, 2026, 1:15 AM EDT - 12 days ago

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

IBB IHE MRNA PJP SMMT XBI

Merck says FDA accepts sBLA for enflonsia

2026-08-06T12:11:53.000Z - 12 days ago

Merck says FDA accepts sBLA for enflonsia

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Aug 6, 2026, 6:45 AM EDT - 13 days ago

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

2026-08-05T15:05:33.000Z - 13 days ago

Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

PFE

Merck price target raised to $116 from $113 at Morgan Stanley

2026-08-05T14:10:13.000Z - 13 days ago

Merck price target raised to $116 from $113 at Morgan Stanley

Merck price target raised to $146 from $145 at Guggenheim

2026-08-05T11:28:42.000Z - 14 days ago

Merck price target raised to $146 from $145 at Guggenheim

Merck & Co. Earnings Call Transcript: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 14 days ago

Merck & Co. Earnings Call Transcript: Q2 2026

Merck & Co. Earnings release: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 14 days ago

Merck & Co. Earnings release: Q2 2026

Merck & Co. Slides: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 14 days ago

Merck & Co. Slides: Q2 2026

Merck & Co. Quarterly report: Q2 2026

Aug 4, 2026, 9:00 AM EDT - 14 days ago

Merck & Co. Quarterly report: Q2 2026

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Aug 4, 2026, 6:41 AM EDT - 15 days ago

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck posts better-than-expected second-quarter results on Keytruda strength

Aug 4, 2026, 6:35 AM EDT - 15 days ago

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Aug 4, 2026, 6:34 AM EDT - 15 days ago

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Aug 4, 2026, 6:30 AM EDT - 15 days ago

Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Aug 4, 2026, 6:30 AM EDT - 15 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co. Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Merck & Co. Transcript: Investor update

Merck & Co. Slides: Investor update

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Merck & Co. Slides: Investor update

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Jul 30, 2026, 1:09 AM EDT - 20 days ago

Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

Merck Announces Fourth-Quarter 2026 Dividend

Jul 29, 2026, 11:04 AM EDT - 20 days ago

Merck Announces Fourth-Quarter 2026 Dividend

Merck licenses experimental HIV pill to generic makers in 129 countries

Jul 24, 2026, 6:48 AM EDT - 26 days ago

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Jul 24, 2026, 6:45 AM EDT - 26 days ago

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Jul 21, 2026, 1:27 PM EDT - 4 weeks ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

GILD

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Jul 21, 2026, 10:00 AM EDT - 4 weeks ago

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

GILD

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Jul 20, 2026, 2:00 AM EDT - 4 weeks ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

Jul 17, 2026, 8:46 AM EDT - 4 weeks ago

Use These ETFs as Health Stocks LLY, UNH, MRK Thrive

LLY UNH PPH VHT XLV

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Jul 17, 2026, 8:40 AM EDT - 4 weeks ago

New Cholesterol Pill, Earnings Growth Boost Merck Shares

Why Healthcare Stocks Look Like a Haven in This Market

Jul 16, 2026, 5:07 PM EDT - 4 weeks ago

Why Healthcare Stocks Look Like a Haven in This Market

XLV

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Jul 16, 2026, 2:14 PM EDT - 4 weeks ago

FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind

Merck's cholesterol pill gets US FDA approval

Jul 16, 2026, 6:49 AM EDT - 4 weeks ago

Merck's cholesterol pill gets US FDA approval

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Jul 16, 2026, 6:45 AM EDT - 4 weeks ago

The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Jul 16, 2026, 6:45 AM EDT - 4 weeks ago

Merck Gets Approval for Powerful Cholesterol-Cutting Pill

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Jul 16, 2026, 6:45 AM EDT - 4 weeks ago

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Jul 10, 2026, 2:10 PM EDT - 5 weeks ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Jul 1, 2026, 6:45 AM EDT - 7 weeks ago

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 7 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

ABBV

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Jun 29, 2026, 5:08 PM EDT - 7 weeks ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Jun 29, 2026, 6:45 AM EDT - 7 weeks ago

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

The Big 3: JPM, DHR, MRK

Jun 25, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: JPM, DHR, MRK

DHR JPM

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Jun 25, 2026, 6:45 AM EDT - 7 weeks ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Jun 24, 2026, 6:45 AM EDT - 2 months ago

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Merck's bowel disease drug meets main goal in late-stage trial

Jun 22, 2026, 7:16 AM EDT - 2 months ago

Merck's bowel disease drug meets main goal in late-stage trial

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Jun 22, 2026, 6:45 AM EDT - 2 months ago

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Jun 18, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Jun 17, 2026, 6:45 AM EDT - 2 months ago

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Jun 12, 2026, 4:10 PM EDT - 2 months ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Merck Animal Health to Acquire TARGAN

Jun 11, 2026, 6:45 AM EDT - 2 months ago

Merck Animal Health to Acquire TARGAN

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY NVO PFE

corruptmarket
corruptmarket Aug. 19 at 11:59 AM
$MRK can we get 160 today?
0 · Reply
SelfMafia
SelfMafia Aug. 19 at 11:58 AM
$TEM People just finding out that they used the $PSNL platform that $TEM now owns? $MRNA $XBI $MRK 😝
0 · Reply
vermigli
vermigli Aug. 19 at 11:57 AM
$MRK $MRNA I’ve seen this movie before. This is either really great news or how the zombie apocalypse starts!
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 19 at 11:56 AM
$PSNL Holding for a $MRK bid
0 · Reply
bizness1957
bizness1957 Aug. 19 at 11:55 AM
$ARDX $XBI index getting a lift on $MRNA and $MRK phase III results.
0 · Reply
Chickenstick1
Chickenstick1 Aug. 19 at 11:53 AM
$MRNA Wow, what a day... A logistical night it may be with the individualization of each vaccine but incredibly encouraging results. Of course, $MRK could handle the flow, but I think $PFE may get a piece of the action, too. Individualization was always the path forward for MRNA vaccines. Congrats to the guys over at $MRNA , well deserved. The market is going to extrapolate from skin to most tumors.
0 · Reply
PittsburghTrader
PittsburghTrader Aug. 19 at 11:53 AM
$MRK sweet, no Luv yesterday but today a party
0 · Reply
arnolddunn
arnolddunn Aug. 19 at 11:53 AM
$MRK Boo yah! …wish I owned Moderna.
0 · Reply
EingeLTrade
EingeLTrade Aug. 19 at 11:52 AM
MERCK $MRK AND MODERNA $MRNA JUST HIT THE FIRST POSITIVE PHASE 3 RESULT EVER FOR A PERSONALIZED CANCER VACCINE!!!
0 · Reply
yus37
yus37 Aug. 19 at 11:51 AM
$MRNA $MRK
0 · Reply
LiveSquawk
LiveSquawk Aug. 19 at 11:50 AM
$MRK $MRNA | Moderna Shares Extend Surge To 102%, Merck Shares Jump 8.3%
0 · Reply
Wallskeet
Wallskeet Aug. 19 at 11:48 AM
$SLS Let's go! $MRK $MRNA
0 · Reply
clan
clan Aug. 19 at 11:48 AM
$MRK $NVAX $MRNA Open your 👀 ! For the good of all Mannkind! #pipeline #technosphere 🇺🇲💪🇺🇲
0 · Reply
yus37
yus37 Aug. 19 at 11:47 AM
$MRNA 🔥 $MRK🔥 #Merck and #Moderna personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial. 🧬💥 Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer❤️💪 $IOVA $IBRX $XBI
1 · Reply
ConcernedCitizen23
ConcernedCitizen23 Aug. 19 at 11:46 AM
$IMNN amazing news from $MRNA and $MRK this am for melanoma. Ovarian cancer not mentioned for this mRNA technology! $IMNN still has the best new tech
0 · Reply
goldenboyx3
goldenboyx3 Aug. 19 at 11:44 AM
🚨 BREAKING: $MRNA $MRK CURE CANCER JUST IN: TRUMP TO DELIVER REMARKS WITH TECHNOLOGY LEADERS AT 2:30 PM ET WEDNESDAY $MRNA 8/21 70C — only cost $0.10 at closing bell yesterday
0 · Reply
Themadogtrader
Themadogtrader Aug. 19 at 11:43 AM
$MRK as a doctor you’re full of shit it’s been known for hundreds of years that cancer can be cured and most of its caused by parasites so as a doctor, you’re a fucking idiot the cure for most of these existed in the 1800s and then Rockefeller decided to destroy all education and reeducate the stupid
0 · Reply
howardlindzon
howardlindzon Aug. 19 at 11:43 AM
$MRK oncology !!! shouda coulda
0 · Reply
howardlindzon
howardlindzon Aug. 19 at 11:42 AM
$MRK big breakout …
0 · Reply
john116868
john116868 Aug. 19 at 11:41 AM
$MRK today gonna be a big ass payday and $MRNA i thought i was gonna be bagged as fuck
3 · Reply
RookyMoves
RookyMoves Aug. 19 at 11:40 AM
$MRK shame this isnt over 150
0 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 19 at 11:39 AM
$MRNA up over 60% pharmas moving $MRK 10% $EYPT RECOVERING C/0 buying $TENX bunch of sc 13g over 22 million with 37 million outstanding $KPTI still august submission of sdna is this month
0 · Reply